BOTOX® Cosmetic (onabotulinumtoxinA) Unveils "The One & Only" Campaign Featuring Real People and Their Distinctive Stories
AbbVie's (NYSE:ABBV) subsidiary Allergan Aesthetics has launched its largest-ever marketing campaign for BOTOX® Cosmetic titled 'The One & Only.' The campaign showcases real patients and their unique stories across multiple media channels including TV, digital, and out-of-home advertising.
As the #1 selling neurotoxin worldwide, BOTOX® Cosmetic has achieved significant milestones with over 100 million vials sold globally and maintains the most FDA-approved aesthetic indication areas in its category. Market research indicates strong customer satisfaction, with 77% of treated consumers considering it worth the cost and 91% of patients expressing intent to continue treatment.
The product recently received recognition as 'Best Injectable' in the 2025 Cosmopolitan Readers' Choice Beauty Awards and continues to be the most trusted choice among aesthetic providers, with 95% of specialists choosing it for themselves, friends, and family.
La controllata di AbbVie (NYSE:ABBV), Allergan Aesthetics, ha lanciato la sua campagna pubblicitaria più ampia di sempre per BOTOX® Cosmetic, intitolata «The One & Only». La campagna mette in luce persone reali e le loro storie individuali attraverso più canali media, tra cui TV, digitale e affissioni.
In qualità di neurotossina più venduta al mondo, BOTOX® Cosmetic ha raggiunto traguardi importanti con oltre 100 milioni di fiale vendute a livello globale e mantiene il maggior numero di approvazioni FDA per indicazioni estetiche nella sua categoria. Le ricerche di mercato mostrano un’elevata soddisfazione: il 77% dei consumatori trattati ritiene che valga il costo e il 91% dei pazienti dichiara l’intenzione di proseguire i trattamenti.
Il prodotto è stato recentemente riconosciuto come «Best Injectable» nei Cosmopolitan Readers' Choice Beauty Awards 2025 e rimane la scelta più affidabile tra i professionisti dell’estetica, con il 95% degli specialisti che lo preferisce per sé, amici e familiari.
La filial de AbbVie (NYSE:ABBV), Allergan Aesthetics, ha lanzado su mayor campaña de marketing hasta la fecha para BOTOX® Cosmetic, titulada «The One & Only». La campaña presenta a pacientes reales y sus historias únicas a través de múltiples canales mediáticos, incluyendo TV, digital y publicidad exterior.
Como la neurotoxina número 1 en ventas a nivel mundial, BOTOX® Cosmetic ha alcanzado hitos significativos con más de 100 millones de viales vendidos globalmente y mantiene la mayor cantidad de indicaciones estéticas aprobadas por la FDA en su categoría. Las investigaciones de mercado indican una sólida satisfacción del cliente: el 77% de los consumidores tratados considera que merece el coste y el 91% de los pacientes manifiesta la intención de continuar el tratamiento.
El producto fue recientemente reconocido como «Best Injectable» en los Cosmopolitan Readers' Choice Beauty Awards 2025 y sigue siendo la opción de mayor confianza entre los profesionales estéticos, con un 95% de especialistas que lo eligen para sí mismos, amigos y familiares.
AbbVie's(NYSE:ABBV) 자회사인 Allergan Aesthetics가 BOTOX® Cosmetic의 역대 최대 마케팅 캠페인 ‘The One & Only’를 시작했습니다. 이번 캠페인은 TV, 디지털, 옥외 광고 등 다양한 매체를 통해 실제 환자들과 그들의 고유한 스토리를 보여줍니다.
전 세계 판매 1위 신경독소인 BOTOX® Cosmetic은 전 세계 1억 병 이상 판매라는 중요한 이정표를 달성했으며, 해당 카테고리에서 가장 많은 FDA 승인 미용 적응증을 보유하고 있습니다. 시장 조사에 따르면 고객 만족도가 높아 치료받은 소비자의 77%가 비용 대비 가치가 있다고 평가했으며, 환자의 91%는 치료를 계속할 의향이 있다고 응답했습니다.
이 제품은 최근 2025 Cosmopolitan Readers' Choice Beauty Awards에서 ‘Best Injectable’로 선정되었고, 미용 시술 제공자들 사이에서 가장 신뢰받는 선택으로 남아 있으며 전문가의 95%가 본인과 친구·가족에게 권한다고 답했습니다.
La filiale d’AbbVie (NYSE:ABBV), Allergan Aesthetics, a lancé sa plus grande campagne marketing à ce jour pour BOTOX® Cosmetic, intitulée « The One & Only ». La campagne met en avant de vrais patients et leurs histoires singulières à travers plusieurs médias, dont la TV, le digital et l’affichage extérieur.
En tant que neurotoxine la plus vendue au monde, BOTOX® Cosmetic a franchi des étapes importantes avec plus de 100 millions de flacons vendus à l’échelle mondiale et détient le plus grand nombre d’indications esthétiques approuvées par la FDA dans sa catégorie. Les études de marché montrent une forte satisfaction client : 77 % des consommateurs traités estiment que le coût en vaut la peine et 91 % des patients ont l’intention de poursuivre le traitement.
Le produit a récemment été élu « Best Injectable » lors des Cosmopolitan Readers' Choice Beauty Awards 2025 et demeure le choix le plus fiable parmi les praticiens esthétiques, 95 % des spécialistes le recommandant pour eux-mêmes, leurs amis et leur famille.
Die Tochtergesellschaft von AbbVie (NYSE:ABBV), Allergan Aesthetics, hat ihre bisher größte Marketingkampagne für BOTOX® Cosmetic mit dem Titel „The One & Only“ gestartet. Die Kampagne zeigt echte Patientinnen und Patienten und ihre persönlichen Geschichten über mehrere Medienkanäle, darunter TV, Digital und Außenwerbung.
Als weltweit meistverkauftes Neurotoxin hat BOTOX® Cosmetic bedeutende Meilensteine erreicht, mit über 100 Millionen verkauften Ampullen weltweit, und verfügt über die meisten FDA-zugelassenen ästhetischen Indikationen in seiner Kategorie. Marktforschungen zeigen hohe Kundenzufriedenheit: 77 % der behandelten Konsumenten halten die Behandlung für ihr Geld wert und 91 % der Patienten beabsichtigen, die Behandlung fortzusetzen.
Das Produkt wurde kürzlich bei den 2025 Cosmopolitan Readers' Choice Beauty Awards als „Best Injectable“ ausgezeichnet und bleibt die vertrauenswürdigste Wahl unter ästhetischen Anbietern, wobei 95 % der Spezialisten es für sich selbst sowie für Freunde und Familie wählen.
- Market leadership position as #1 selling neurotoxin worldwide
- Strong customer satisfaction with 77% considering it worth the cost
- High retention rate with 91% of patients planning to continue treatment
- 95% of specialists choose it for themselves, friends, and family
- Over 100 million vials sold globally
- Most FDA-approved aesthetic indication areas in its category
- None.
- Building on the brand's 20-year legacy and real-world experience, the original BOTOX® Cosmetic continues to be the most researched and requested product of its kind.1,2
- BOTOX® Cosmetic is trusted by aesthetic providers with
95% of specialists choosing it for themselves, their friends, and family.3 - This campaign is BOTOX® Cosmetic's largest ever, appearing across national linear and connected TV, digital, social, and out-of-home.
The One & Only campaign features real, everyday people, both new and repeat patients, treated with BOTOX® Cosmetic. The campaign depicts each person doing what they love, while showing off their individuality. The One & Only campaign demonstrates that patients are their same unique selves, even after treatment. The tagline for the campaign is, "The one & only BOTOX® Cosmetic. The one & only you."
"Just as each person is distinct, so too are their aesthetic goals. As a champion of authenticity, Allergan Aesthetics' new campaign features real people, not actors, who rely on BOTOX® Cosmetic's precise, predictable results," said Glen Curran, Senior Vice President,
BOTOX® Cosmetic is the product patients ask for by name and tell others about, with market research showing that 77 percent of treated consumers believe it is worth the cost.11* It is also the product patients keep coming back for; 91 percent of patients say they will continue using BOTOX® Cosmetic if their specialist says they are right for treatment.12† Additionally, Cosmopolitan magazine recently recognized BOTOX® Cosmetic as "Best Injectable" in the 2025 Cosmopolitan Readers' Choice Beauty Awards, with readers saying, "BOTOX® Cosmetic continues to be the one you depend on; it's the one and only."
FDA-approved for more than 20 years, BOTOX® Cosmetic continues to lead the market with more than 100 million vials sold globally.4,10 The brand has four FDA-approved aesthetic indication areas, the most in the category, including moderate to severe frown lines, crow's feet lines, forehead lines, and vertical bands connecting the neck and jaw (platysma bands) in adults.4
The One & Only campaign will run across national linear and connected television, digital, social, and out-of-home. Those interested in learning more about BOTOX® Cosmetic and The One & Only campaign can visit botoxcosmetic.com and enroll in Allē, the leading aesthetics loyalty program from Allergan Aesthetics.
*Based on a 2023 online survey of 233 BOTOX® Cosmetic users.11
†Based on a 2023 online survey of 258 BOTOX® Cosmetic users who strongly or somewhat agreed they would continue receiving BOTOX® Cosmetic treatment.12
About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.
IMPORTANT SAFETY INFORMATION
BOTOX® Cosmetic may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX® Cosmetic:
- Problems swallowing, speaking, or breathing, due to weakening of associated muscles, which can be severe and result in loss of life. You are at the highest risk if these problems are preexisting before injection. Swallowing problems may last for several months.
- Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms, including loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing.
BOTOX® Cosmetic dosing units are not the same as, or comparable to, any other botulinum toxin product.
There has not been a confirmed serious case of spread of toxin effect when BOTOX® Cosmetic has been used at the recommended dose to treat frown lines, crow's feet lines, forehead lines, and/or platysma bands.
BOTOX® Cosmetic may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks of receiving BOTOX® Cosmetic. If this happens, do not drive a car, operate machinery, or do other dangerous activities.
Serious and/or immediate allergic reactions have been reported, including itching, rash, red itchy welts, wheezing, asthma symptoms, or dizziness or feeling faint. Get medical help right away if you are wheezing or have asthma symptoms, or if you become dizzy or faint.
Do not receive BOTOX® Cosmetic if you are allergic to any of the ingredients in BOTOX® Cosmetic (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc (rimabotulinumtoxinB), Dysport (abobotulinumtoxinA), Xeomin (incobotulinumtoxinA), Jeuveau (prabotulinumtoxinA-xvfs), Daxxify (daxibotulinumtoxinA-lanm), or Letybo (letibotulinumtoxinA-wlbg); or have a skin infection at the planned injection site. This list may not include all available botulinum toxin products.
Tell your doctor about all your muscle or nerve conditions, such as ALS or Lou Gehrig's disease, myasthenia gravis, or Lambert-Eaton syndrome, as you may be at increased risk of serious side effects, including difficulty swallowing and difficulty breathing, from standard doses of BOTOX® Cosmetic.
Tell your doctor about all your medical conditions, including surgery or plans to have surgery on your face, trouble raising your eyebrows, drooping eyelids, any other abnormal facial change, are pregnant or plan to become pregnant (it is not known if BOTOX® Cosmetic can harm your unborn baby), or are breastfeeding or plan to (it is not known if BOTOX® Cosmetic passes into breast milk).
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using BOTOX® Cosmetic with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your doctor that you have received BOTOX® Cosmetic in the past.
Tell your doctor if you have received any other botulinum toxin product in the last 4 months; have received injections of botulinum toxin such as Myobloc, Dysport, Xeomin, Jeuveau, Daxxify, or Letybo in the past (tell your doctor exactly which product you received); have recently received an antibiotic by injection; take muscle relaxants; take an allergy or cold medicine; take a sleep medicine; or take aspirin-like products or blood thinners.
Other side effects of BOTOX® Cosmetic include dry mouth; discomfort or pain at the injection site; tiredness; headache; neck pain; and eye problems, including double vision, blurred vision, decreased eyesight, drooping eyelids and eyebrows, swelling of eyelids, and dry eyes.
For more information, refer to the Medication Guide or talk with your doctor.
To report a side effect, please call Allergan Aesthetics at 1-800-678-1605.
Please see BOTOX® Cosmetic full Prescribing Information, including Boxed Warning and Medication Guide.
References:
- Data on File. Allergan, Botulinum Toxin Peer-Reviewed Publications, January 2024.
- Data on File. AbbVie, Neurotoxin Monthly Tracker Report, January 2025.
- Data on File. Allergan, Choosing Botox Quick Quant Study, July 2023
- BOTOX® Cosmetic Prescribing Information, October 2024.
- Dysport® Prescribing Information, September 2023.
- Xeomin® Prescribing Information, July 2024.
- Jeuveau® Prescribing Information, April 2023.
- Daxxify® Prescribing Information, November 2023.
- Letybo® Prescribing Information, February 2024
- Data on File, Total Number of BOTOX Vials, December 2022
- Data on File. Allergan, Neurotoxin Facial Injectables Consumer A&U, 2024.
- Data on File. Allergan, BOTOX® Cosmetic Claims Assessment, April 2023.
Contact(s)
Investors:
Liz Shea
Liz.Shea@AbbVie.com
(847) 935-2211
Media:
Ember Garrett
Ember.Garrett@allergan.com
(714) 246-3525
© 2025 AbbVie. All rights reserved. BOTOX® Cosmetic and its designs are trademarks of Allergan Holdings France SAS, and AbbVie company, or its affiliates. All other trademarks are the property of their respective owners.
View original content to download multimedia:https://www.prnewswire.com/news-releases/botox-cosmetic-onabotulinumtoxina-unveils-the-one--only-campaign-featuring-real-people-and-their-distinctive-stories-302550142.html
SOURCE AbbVie
FAQ
What is AbbVie's new 'The One & Only' BOTOX® Cosmetic campaign about?
How many BOTOX® Cosmetic vials have been sold globally by AbbVie (ABBV)?
What percentage of specialists choose BOTOX® Cosmetic for themselves and family?
What are the FDA-approved aesthetic indication areas for BOTOX® Cosmetic?
What is the patient satisfaction rate for BOTOX® Cosmetic treatments?
